or Try an Advanced Search...

    Technical Analysis for GANX - Gain Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.62 11.97% 0.28
    GANX closed up 11.97 percent on Wednesday, May 15, 2024, on 1.32 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GANX trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 11.97%
    Wide Bands Range Expansion 11.97%
    Gapped Up Strength 11.97%
    Below Lower BB Weakness 11.97%
    Down 3 Days in a Row Weakness 11.97%
    Down 4 Days in a Row Weakness 11.97%
    Older End-of-Day Signals for GANX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 14 hours ago
    Up 1 ATR about 14 hours ago
    2x Volume Pace about 17 hours ago
    Gap Up Partially Closed about 18 hours ago
    1.5x Volume Pace about 18 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    GANX Chart by TradingView
    Basic chart:

    Profile

    Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group

    Is GANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Gain Therapeutics GAAP EPS of -$0.22
    May 14 Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
    May 3 Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
    Apr 24 Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    Apr 17 Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
    Apr 10 Insiders are Piling into These 10 Healthcare Stocks in 2024
    Apr 10 Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
    Apr 9 Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
    Apr 8 Gain Therapeutics names Gene Mack as CFO
    Apr 8 Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
    See more GANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.33
    52 Week Low 2.0
    Average Volume 110,702
    200-Day Moving Average 3.41
    50-Day Moving Average 3.51
    20-Day Moving Average 2.89
    10-Day Moving Average 2.68
    Average True Range 0.28
    RSI (14) 36.31
    ADX 32.66
    +DI 10.26
    -DI 20.18
    Chandelier Exit (Long, 3 ATRs) 2.81
    Chandelier Exit (Short, 3 ATRs) 3.18
    Upper Bollinger Bands 3.45
    Lower Bollinger Band 2.33
    Percent B (%b) 0.26
    BandWidth 38.60
    MACD Line -0.28
    MACD Signal Line -0.26
    MACD Histogram -0.0144
    Fundamentals Value
    Market Cap 42.44 Million
    Num Shares 16.2 Million
    EPS -1.81
    Price-to-Earnings (P/E) Ratio -1.45
    Price-to-Sales 1400.35
    Price-to-Book 10.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.99
    Resistance 3 (R3) 2.96 2.81 2.93
    Resistance 2 (R2) 2.81 2.71 2.82 2.91
    Resistance 1 (R1) 2.71 2.65 2.76 2.74 2.89
    Pivot Point 2.56 2.56 2.58 2.57 2.56
    Support 1 (S1) 2.46 2.46 2.51 2.50 2.35
    Support 2 (S2) 2.31 2.40 2.32 2.33
    Support 3 (S3) 2.21 2.31 2.31
    Support 4 (S4) 2.25